628 Spam-Free Article(s) Found
Symbol Name Last Close Mkt Cap DailyStocks'
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Wednesday’s Close
LLY Eli Lilly and Company $105.71 $113.53B N/A
Article Searches
Drug/Biotech Stock Q3 Earnings on Oct 23: LLY, ALXN & More http://www.zacks.com/stock/news/577360/drug-biotech-stock-q3-earnings-on-oct-23-lly-alxn-more?cid=CS-ZC-FT-analyst_blog:_earnings_preview_-_esp|earnings_preview_-_esp-577360 Oct 22, 2019 - Four drug/biotech stocks are scheduled to release third-quarter results on Oct 23. Let's see how these companies are placed before their earnings call.
Lilly's Pancreatic Cancer Candidate Fails in Phase III Study http://www.zacks.com/stock/news/569619/lillys-pancreatic-cancer-candidate-fails-in-phase-iii-study?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-569619 Oct 17, 2019 - Lilly's (LLY) immunotherapy candidate, pegilodecakin, falls short of meeting the primary endpoint of OS benefit in a phase III study investigating its usage in metastatic pancreatic cancer.
Can New Drugs Help Lilly (LLY) to Deliver Solid Q3 Earnings? http://www.zacks.com/stock/news/569574/can-new-drugs-help-lilly-lly-to-deliver-solid-q3-earnings?cid=CS-ZC-FT-analyst_blog|earnings_preview-569574 Oct 17, 2019 - Eli Lilly and Company's (LLY) new drugs like Trulicity, Taltz and Jardiance are likely to have performed well. Let's see if these along with its older products lead to an earnings beat for the company in Q3.
Eli Lilly (LLY) Reports Next Week: Wall Street Expects Earnings Growth http://www.zacks.com/stock/news/567502/eli-lilly-lly-reports-next-week-wall-street-expects-earnings-growth?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_9-567502 Oct 16, 2019 - Lilly (LLY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
3 Dividend-Paying Pharma Stocks to Buy Now https://www.fool.com/investing/2019/10/15/3-dividend-paying-pharma-stocks-to-buy-now.aspx?source=iedfolrf0000001 Oct 15, 2019 - These aren't the highest payouts in the industry, but they have the best chance to steadily climb.
Lilly Gets FDA Approval for New Oral Tablets for Migraine http://www.zacks.com/stock/news/563662/lilly-gets-fda-approval-for-new-oral-tablets-for-migraine?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-563662 Oct 14, 2019 - Eli Lilly (LLY) gets FDA approval for lasmiditan oral tablets to treat acute migraine in adults.
Pharma Stock Roundup: NVS' New Eye Drug Gets FDA Nod, NVO, GSK, PFE Sign Deals http://www.zacks.com/stock/news/559573/pharma-stock-roundup-nvs-new-eye-drug-gets-fda-nod-nvo-gsk-pfe-sign-deals?cid=CS-ZC-FT-analyst_blog|stock_roundup-559573 Oct 11, 2019 - FDA approves Novartis' (NVS) Beovu. J&J (JNJ) files sBLA for Stelara. Pfizer (PFE), Novo Nordisk (NVO) and Glaxo (GSK) announce collaboration deals.
3 Big Drug/Biotech Stocks Set to Beat Q3 Earnings Estimates http://www.zacks.com/stock/news/557902/3-big-drug-biotech-stocks-set-to-beat-q3-earnings-estimates?cid=CS-ZC-FT-earnings_esp-557902 Oct 10, 2019 - Here we highlight three bigshot drug/biotech companies, which are expected to deliver positive earnings surprises in Q3.
J&J (JNJ) to Start Q3 Earnings Season for Pharma Sector http://www.zacks.com/stock/news/557845/jj-jnj-to-start-q3-earnings-season-for-pharma-sector?cid=CS-ZC-FT-analyst_blog|earnings_preview-557845 Oct 10, 2019 - J&J's (JNJ) cancer drugs are expected to contribute significantly to third-quarter 2019 earnings. Generic/biosimilar headwinds are expected to hurt Pharma unit's sales.
Gilead (GILD) Files NDA for RA Candidate Filgotinib in Japan http://www.zacks.com/stock/news/556224/gilead-gild-files-nda-for-ra-candidate-filgotinib-in-japan?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-556224 Oct 09, 2019 - Gilead's (GILD) new drug application for its JAK1 inhibitor filgotinib seeks treatment of rheumatoid arthritis in adult patients across Japan.

Pages: 123456...63

Page 1>